

# Metastasis Stage, Adjuvant Treatment, and Residual Tumor in Children With Medulloblastoma: Conclusions From the Children's Cancer Group Randomized Phase III Study

Journal of Clinical Oncology

17, 832-832

DOI: 10.1200/jco.1999.17.3.832

Citation Report

#	ARTICLE	IF	CITATIONS
1	Chemotherapy of medulloblastoma. Child's Nervous System, 1999, 15, 554-562.	1.1	21
2	Treatment strategies for medulloblastoma and primitive neuroectodermal tumors. Neurosurgical Focus, 1999, 7, E3.	2.3	4
4	Correlation of Neurosurgical Subspecialization with Outcomes in Children with Malignant Brain Tumors. Neurosurgery, 2000, 47, 879-887.	1.1	123
5	Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse. Neurosurgery, 2000, 47, 623-632.	1.1	165
6	Adult Medulloblastoma: Prognostic Factors and Patterns of Relapse. Neurosurgery, 2000, 47, 623-632.	1.1	119
7	Prognostic factors for medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2000, 47, 573-584.	0.8	59
8	Medulloblastomaâ€”challenges in radiation therapy and the addition of chemotherapy. International Journal of Radiation Oncology Biology Physics, 2000, 46, 261-263.	0.8	9
9	Postoperative neoadjuvant chemotherapy before radiotherapy as compared to immediate radiotherapy followed by maintenance chemotherapy in the treatment of medulloblastoma in childhood: results of the german prospective randomized trial hit â€™91. International Journal of Radiation Oncology Biology Physics, 2000, 46, 269-279.	0.8	382
10	Medulloblastoma in children - the Ottawa experience. Child's Nervous System, 2000, 16, 341-350.	1.1	28
11	Proton Magnetic Resonance Spectroscopic Imaging in Children With Recurrent Primary Brain Tumors. Journal of Clinical Oncology, 2000, 18, 1020-1020.	1.6	99
12	NOVEL CHEMOTHERAPEUTIC APPROACHES TO BRAIN TUMORS. Hematology/Oncology Clinics of North America, 2001, 15, 1027-1052.	2.2	18
13	Prognostic Factors and Secondary Malignancies in Childhood Medulloblastoma. The American Journal of Pediatric Hematology/oncology, 2001, 23, 431-436.	1.3	101
14	Abundance of Apoptotic Neoplastic Cells in Diagnostic Biopsy Samples Is not a Prognostic Factor in Childhood Primitive Neuroectodermal Tumors of the Central Nervous System. The American Journal of Pediatric Hematology/oncology, 2001, 23, 25-29.	1.3	10
15	Treatment controversies in medulloblastoma. Current Opinion in Oncology, 2001, 13, 154-159.	2.4	25
17	Advances in biology and treatment of childhood brain tumors. Current Neurology and Neuroscience Reports, 2001, 1, 137-143.	4.2	22
18	Radiosurgery in the management of pediatric brain tumors. International Journal of Radiation Oncology Biology Physics, 2001, 50, 929-935.	0.8	106
19	Prognostic significance of Ki-67 (MIB-1) proliferation index in childhood primitive neuroectodermal tumors of the central nervous system. Medical and Pediatric Oncology, 2001, 36, 268-273.	1.0	31
20	Atypical teratoid/rhabdoid tumors in adult patients: case report and review of the literature. Journal of Neuro-Oncology, 2001, 52, 49-56.	2.9	71

#	ARTICLE	IF	CITATIONS
21	Shunt-related abdominal metastases in an infant with medulloblastoma: long-term remission by systemic chemotherapy and surgery. <i>Journal of Neuro-Oncology</i> , 2001, 52, 273-276.	2.9	20
22	A mouse model for medulloblastoma and basal cell nevus syndrome. , 2001, 53, 307-318.		80
24	Radiation therapy in the management of childhood brain tumors. <i>Child's Nervous System</i> , 2001, 17, 121-133.	1.1	57
25	Expression profiling of medulloblastoma: PDGFRA and the RAS/MAPK pathway as therapeutic targets for metastatic disease. <i>Nature Genetics</i> , 2001, 29, 143-152.	21.4	421
26	Review of the molecular genetics and chemotherapeutic treatment of adult and paediatric medulloblastoma. <i>Expert Opinion on Investigational Drugs</i> , 2001, 10, 2089-2104.	4.1	17
27	Clinical and molecular stratification of disease risk in medulloblastoma. <i>British Journal of Cancer</i> , 2001, 85, 705-712.	6.4	154
28	Survival and recurrence factors in adult medulloblastoma: The M.D. Anderson Cancer Center experience from 1978 to 1998. <i>Neuro-Oncology</i> , 2001, 3, 167-173.	1.2	70
29	High Microvessel Density in Primitive Neuroectodermal Brain Tumors of Childhood. <i>Neuropediatrics</i> , 2001, 32, 75-79.	0.6	31
31	Medulloblastoma Metastatic to the Suprasellar Region at Diagnosis: A Report of Six Cases with Clinicopathologic Correlation. <i>Pediatric Neurosurgery</i> , 2002, 37, 111-117.	0.7	20
32	MDM2 overexpression is associated with short survival in adults with medulloblastoma. <i>Neuro-Oncology</i> , 2002, 4, 115-122.	1.2	33
33	Brain tumours in children. , 2002, , 1448-1461.		0
34	Recent advances in paediatric neuro-oncology. <i>Current Opinion in Neurology</i> , 2002, 15, 671-677.	3.6	18
35	Medulloblastomas With Favorable Versus Unfavorable Histology: How Many Small Blue Cell Tumor Types are There in the Brain?. <i>Advances in Anatomic Pathology</i> , 2002, 9, 345-350.	4.3	30
36	Metastatic medulloblastomaâ€”therapeutic success through molecular target identification?. <i>Pharmacogenomics Journal</i> , 2002, 2, 7-10.	2.0	13
37	Expression of Apo-3 and Apo-3L in primitive neuroectodermal tumours of the central and peripheral nervous system. <i>European Journal of Cancer</i> , 2002, 38, 92-98.	2.8	22
38	Loss of caspase-8 mRNA expression is common in childhood primitive neuroectodermal brain tumour/medulloblastoma. <i>European Journal of Cancer</i> , 2002, 38, 83-91.	2.8	212
39	Embryonal tumours of the central nervous system. <i>European Journal of Cancer</i> , 2002, 38, 1112-1120.	2.8	10
40	Recent advances in paediatric neuro-oncology. <i>Current Opinion in Neurology</i> , 2002, 15, 671-677.	3.6	21

#	ARTICLE	IF	CITATIONS
41	Radiotherapy for medulloblastoma in children: A perspective on current international clinical research efforts. <i>Medical and Pediatric Oncology</i> , 2002, 39, 99-108.	1.0	62
42	Preliminary results of dose intensive pre-irradiation chemotherapy in patients older than 10 years of age with high risk medulloblastoma and supratentorial primitive neuroectodermal tumors. <i>Medical and Pediatric Oncology</i> , 2002, 38, 47-48.	1.0	11
43	Histopathologic grading of medulloblastomas. <i>Cancer</i> , 2002, 94, 552-560.	4.1	298
44	Risk assignment in childhood brain tumors: The emerging role of molecular and biologic classification. <i>Current Oncology Reports</i> , 2002, 4, 114-122.	4.0	11
45	Survival of children under 3 years old with medulloblastoma: a study from the Mexican Cooperative Group for Childhood Malignancies (AMOHP). <i>Child's Nervous System</i> , 2002, 18, 38-42.	1.1	4
46	Classifying the medulloblastoma: insights from morphology and molecular genetics. <i>Neuropathology and Applied Neurobiology</i> , 2002, 28, 257-282.	3.2	195
47	Cytogenetic evaluation of isochromosome 17q in posterior fossa tumors of children and correlation with clinical outcome in medulloblastoma. <i>Child's Nervous System</i> , 2002, 18, 380-384.	1.1	13
48	Delay in the diagnosis of paediatric brain tumours. <i>European Journal of Pediatrics</i> , 2002, 161, 663-667.	2.7	119
49	Immunohistochemical markers for prognosis of average-risk pediatric medulloblastomas. The effect of apoptotic index, TrkC, and c-myc expression. <i>Journal of Neuro-Oncology</i> , 2002, 58, 271-279.	2.9	29
50	Current multimodality management of medulloblastoma. <i>Current Problems in Cancer</i> , 2002, 26, 317-356.	2.0	16
51	An Audit of Delays Before and During Radical Radiotherapy for Cervical Cancer—Effect on Tumour Cure Probability. <i>Clinical Oncology</i> , 2003, 15, 47-54.	1.4	43
52	Medulloblastomas and central nervous system primitive neuroectodermal tumors. <i>Current Treatment Options in Oncology</i> , 2003, 4, 499-508.	3.0	9
53	Gene expression profiling to analyze embryonal tumors of the central nervous system. <i>Current Neurology and Neuroscience Reports</i> , 2003, 3, 117-119.	4.2	1
54	Medulloblastome im Erwachsenenalter. <i>Onkologe</i> , 2003, 9, 710-720.	0.7	3
55	Evaluation of dietetic intervention in children with medulloblastoma or supratentorial primitive neuroectodermal tumors. <i>Cancer</i> , 2003, 98, 1014-1020.	4.1	51
56	The treatment of adults with medulloblastoma: a prospective study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 755-761.	0.8	82
57	Genetic alterations of human brain tumors as molecular prognostic factors. <i>Neuropathology</i> , 2003, 23, 95-108.	1.2	14
58	The Use of Gene Expression Analysis to Gain Insights into Signaling Mechanisms of Metastatic Medulloblastoma. <i>Pediatric Neurosurgery</i> , 2003, 39, 68-74.	0.7	23

#	ARTICLE	IF	CITATIONS
59	Medulloblastoma: Present Concepts of Stratification into Risk Groups. <i>Pediatric Neurosurgery</i> , 2003, 39, 60-67.	0.7	145
60	Results of a Randomized Study of Preradiation Chemotherapy Versus Radiotherapy Alone for Nonmetastatic Medulloblastoma: The International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 Study. <i>Journal of Clinical Oncology</i> , 2003, 21, 1581-1591.	1.6	318
61	From the Archives of the AFIP. <i>Radiographics</i> , 2003, 23, 1613-1637.	3.3	207
62	Central nervous system tumours in adolescents. <i>European Journal of Cancer</i> , 2003, 39, 2643-2650.	2.8	17
63	Pure subcutaneous seeding from medulloblastoma. <i>Pediatric Neurology</i> , 2003, 29, 245-249.	2.1	11
64	Advances in the Diagnosis, Molecular Genetics, and Treatment of Pediatric Embryonal CNS Tumors. <i>Oncologist</i> , 2003, 8, 174-186.	3.7	78
65	Evaluation of radiotherapy for pediatric CNS tumors. <i>Expert Review of Neurotherapeutics</i> , 2003, 3, 491-500.	2.8	5
66	Medulloblastoma Sensitivity to 17-Allylamino-17-demethoxygeldanamycin Requires MEK/ERK. <i>Journal of Biological Chemistry</i> , 2003, 278, 24951-24959.	3.4	28
67	Protracted Radiotherapy Treatment Duration in Medulloblastoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2003, 26, 55-59.	1.3	28
68	Morphophenotypic Variation Predicts Clinical Behavior in Childhood Non-Desmoplastic Medulloblastomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2003, 62, 627-632.	1.7	107
69	Testing the "Go or Grow" Hypothesis in Human Medulloblastoma Cell Lines in Two and Three Dimensions. <i>Neurosurgery</i> , 2003, 53, 174-185.	1.1	48
70	Multiple systemic metastases of posterior fossa - primitive neuroectodermal tumor (PF-PNET) in adult: case report. <i>Arquivos De Neuro-Psiquiatria</i> , 2003, 61, 100-103.	0.8	3
71	Combined Histopathological and Molecular Cytogenetic Stratification of Medulloblastoma Patients. <i>Clinical Cancer Research</i> , 2004, 10, 5482-5493.	7.0	198
72	Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival. <i>Cancer Research</i> , 2004, 64, 3103-3111.	0.9	139
73	A Clinicobiological Model Predicting Survival in Medulloblastoma. <i>Clinical Cancer Research</i> , 2004, 10, 7613-7620.	7.0	117
74	Combining Gene Expression Profiles and Clinical Parameters for Risk Stratification in Medulloblastomas. <i>Journal of Clinical Oncology</i> , 2004, 22, 994-998.	1.6	81
75	Biologic Risk Stratification of Medulloblastoma: The Real Time Is Now. <i>Journal of Clinical Oncology</i> , 2004, 22, 971-974.	1.6	36
76	Clinical, Histopathologic, and Molecular Markers of Prognosis: Toward a New Disease Risk Stratification System for Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 984-993.	1.6	261

#	ARTICLE	IF	CITATIONS
77	Bcl-2 expression inversely correlates with tumour cell differentiation in medulloblastoma. Neuropathology and Applied Neurobiology, 2004, 30, 513-521.	3.2	21
78	Current treatment of medulloblastoma: Recent advances and future challenges. Seminars in Oncology, 2004, 31, 666-675.	2.2	80
79	High-dose Chemotherapy With Autologous Stem Cell Rescue as First Line of Treatment in Young Children with Medulloblastoma and Supratentorial Primitive Neuroectodermal Tumors. Journal of Neuro-Oncology, 2004, 67, 101-106.	2.9	30
80	Pediatric Surgical Neuro-Oncology: Current Best Care Practices and Strategies. Journal of Neuro-Oncology, 2004, 69, 139-150.	2.9	36
81	Review of the prognostic factors in medulloblastoma of children and adults. Critical Reviews in Oncology/Hematology, 2004, 50, 121-128.	4.4	51
82	Patterns of failure in supratentorial primitive neuroectodermal tumors treated in Children's Cancer Group Study 921, a phase III combined modality study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 204-213.	0.8	31
83	Molecular analysis of pediatric brain tumors. Current Oncology Reports, 2004, 6, 445-452.	4.0	17
84	New treatments in pediatric brain tumors. Current Treatment Options in Neurology, 2004, 6, 377-389.	1.8	3
85	Medulloblastoma in childhood: Impact of radiation technique upon the outcome of treatment. Pediatric Blood and Cancer, 2004, 42, 155-160.	1.5	19
86	Differential responsiveness among "high risk" pediatric brain tumors in a pilot study of dose-intensive induction chemotherapy. Pediatric Blood and Cancer, 2004, 43, 46-54.	1.5	11
87	Impact of radiotherapy parameters on outcome in the International Society of Paediatric Oncology/United Kingdom Children's Cancer Study Group PNET-3 study of preradiotherapy chemotherapy for M0-M1 medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1184-1193.	0.8	68
88	Concurrent chemotherapy and reduced-dose cranial spinal irradiation followed by conformal posterior fossa tumor bed boost for average-risk medulloblastoma: efficacy and patterns of failure. International Journal of Radiation Oncology Biology Physics, 2004, 58, 1161-1164.	0.8	58
89	Prognostic significance of anaplasia and angiogenesis in childhood medulloblastoma: a pediatric oncology group study. Pathology Research and Practice, 2004, 200, 501-509.	2.3	21
90	Dynamic response of cancer under the influence of immunological activity and therapy. Journal of Theoretical Biology, 2004, 227, 335-348.	1.7	109
91	Feasibility and Response to Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma. Journal of Clinical Oncology, 2004, 22, 4881-4887.	1.6	168
94	Expression of MATH1, a marker of cerebellar granule cell progenitors, identifies different medulloblastoma sub-types. Neuroscience Letters, 2004, 370, 180-185.	2.1	51
95	Medulloblastoma: signalling a change in treatment. Lancet Oncology, The, 2004, 5, 209-218.	10.7	276
96	Leptomeningeal Cancer in the Pediatric Patient. , 2005, 125, 87-106.		4

#	ARTICLE	IF	CITATIONS
97	Anaplasia Is Rare and Does Not Influence Prognosis in Adult Medulloblastoma. Journal of Neuropathology and Experimental Neurology, 2005, 64, 869-874.	1.7	22
98	Genomic Profiling in Pediatric Brain Tumors. Cancer Journal (Sudbury, Mass ), 2005, 11, 283-293.	2.0	5
99	Medulloblastoma in the second decade of life: A specific group with respect to toxicity and management. Cancer, 2005, 103, 1874-1880.	4.1	61
100	Recent advances in embryonal tumours of the central nervous system. Child's Nervous System, 2005, 21, 272-293.	1.1	17
101	Adult medulloblastoma. Journal of Neurology, 2005, 252, 291-299.	3.6	76
102	Embryonic tumours of the central nervous system. Clinical and Translational Oncology, 2005, 7, 219-227.	2.4	4
103	High-dose chemotherapy with autologous stem cell rescue for children with high risk and recurrent medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neuro-Oncology, 2005, 71, 33-38.	2.9	80
104	Progress and Challenges in Childhood Brain Tumors. Journal of Neuro-Oncology, 2005, 75, 239-242.	2.9	28
105	Therapeutic schedules influence the pattern of intellectual decline after irradiation of posterior fossa tumors. Pediatric Blood and Cancer, 2005, 45, 814-819.	1.5	49
106	Treatment strategies for high-risk medulloblastoma and supratentorial primitive neuroectodermal tumors. Journal of Neurosurgery: Pediatrics, 2005, 102, 44-52.	1.3	29
107	Long-term Survival of High-Risk Pediatric Patients With Primitive Neuroectodermal Tumors Treated With Antineoplastons A10 and AS2-1. Integrative Cancer Therapies, 2005, 4, 168-177.	2.0	10
109	Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma. Journal of Clinical Oncology, 2005, 23, 8853-8862.	1.6	207
110	Leptomeningeal Neoplasia: Epidemiology, Clinical Presentation, CSF Analysis and Diagnostic Imaging. , 2005, 125, 17-30.		34
111	Neoplasms of the Posterior Fossa. , 2005, , 69-85.		0
112	Biology of Primitive Neuroectodermal Tumors. , 2005, , 125-154.		0
113	Survivin, Survivin-2B, and Survivin-deltaEx3 expression in medulloblastoma: biologic markers of tumour morphology and clinical outcome. British Journal of Cancer, 2005, 92, 359-365.	6.4	52
114	Multiagent Chemotherapy and Deferred Radiotherapy in Infants With Malignant Brain Tumors: A Report From the Children's Cancer Group. Journal of Clinical Oncology, 2005, 23, 7621-7631.	1.6	381
115	Treatment of Early Childhood Medulloblastoma by Postoperative Chemotherapy Alone. New England Journal of Medicine, 2005, 352, 978-986.	27.0	682

#	ARTICLE	IF	CITATIONS
116	Atypical white matter volume development in children following craniospinal irradiation. <i>Neuro-Oncology</i> , 2005, 7, 12-19.	1.2	103
118	Treatment of medulloblastoma with postoperative chemotherapy alone: an SFOP prospective trial in young children. <i>Lancet Oncology</i> , The, 2005, 6, 573-580.	10.7	250
119	Standard-Risk Medulloblastoma Treated by Adjuvant Chemotherapy Followed by Reduced-Dose Craniospinal Radiation Therapy: A French Society of Pediatric Oncology Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 4726-4734.	1.6	132
120	Outcome for patients with metastatic (M2â€³) medulloblastoma treated with SIOP/UKCCSG PNET-3 chemotherapy. <i>European Journal of Cancer</i> , 2005, 41, 727-734.	2.8	138
121	Brain Tumors in Children: Evaluation and Management. <i>Current Problems in Pediatric and Adolescent Health Care</i> , 2005, 35, 230-245.	1.7	19
122	Untreated Pediatric Primitive Neuroectodermal Tumor in Vivo: Quantitation of Taurine with MR Spectroscopy. <i>Radiology</i> , 2005, 236, 1020-1025.	7.3	104
124	Pediatric Neuro-oncology. , 2005, , 489-502.		0
126	State of the art chemotherapeutic management of pediatric brain tumors. <i>Expert Review of Neurotherapeutics</i> , 2006, 6, 765-779.	2.8	7
127	Genomics Identifies Medulloblastoma Subgroups That Are Enriched for Specific Genetic Alterations. <i>Journal of Clinical Oncology</i> , 2006, 24, 1924-1931.	1.6	617
128	Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. <i>Lancet Oncology</i> , The, 2006, 7, 813-820.	10.7	811
129	Phase III Study of Craniospinal Radiation Therapy Followed by Adjuvant Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 4202-4208.	1.6	834
130	Treatment of high risk medulloblastomas in children above the age of 3 years: A SFOP study. <i>European Journal of Cancer</i> , 2006, 42, 3004-3014.	2.8	67
131	Histopathological prognostic factors in medulloblastoma: High expression of survivin is related to unfavourable outcome. <i>European Journal of Cancer</i> , 2006, 42, 2996-3003.	2.8	35
132	Late Relapse of Pediatric Medulloblastoma. <i>Neuroradiology Journal</i> , 2006, 19, 583-588.	1.2	0
134	TrkA expression is associated with an elevated level of apoptosis in classic medulloblastomas. <i>Neuropathology</i> , 2006, 26, 170-177.	1.2	20
135	Quantitative mRNA expression analysis of neurotrophin-receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. <i>Neuropathology</i> , 2006, 26, 393-399.	1.2	11
136	Anaplasia and Grading in Medulloblastomas. <i>Brain Pathology</i> , 2003, 13, 376-385.	4.1	86
137	Distinctive clinical course and pattern of relapse in adolescents with medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 402-407.	0.8	35



#	ARTICLE	IF	CITATIONS
138	Central Nervous System Tumors. , 2006, , 487-505.		1
139	A review of clinical and histological features of Spanish paediatric medulloblastomas during the last 21 years. Child's Nervous System, 2006, 22, 466-474.	1.1	16
140	Monitoring the growth effect of xenotransplanted human medulloblastoma in an immunocompromised mouse model using in vitro and ex vivo green fluorescent protein imaging. Child's Nervous System, 2006, 22, 475-480.	1.1	7
141	Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Child's Nervous System, 2006, 23, 133-136.	1.1	22
142	Dynamic response of cancer under the influence of immunological activity and therapy. Journal of Theoretical Biology, 2006, 240, 162-163.	1.7	26
143	Current therapy for medulloblastoma. Current Treatment Options in Neurology, 2006, 8, 319-334.	1.8	64
144	Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. Genes Chromosomes and Cancer, 2006, 45, 401-410.	2.8	41
145	Current treatment approaches to early childhood medulloblastoma. Expert Review of Neurotherapeutics, 2006, 6, 1211-1221.	2.8	28
146	Familial Central Nervous System Tumor Syndromes. Current Cancer Therapy Reviews, 2006, 2, 281-291.	0.3	0
147	Prognostic Relevance of Clinical and Biological Risk Factors in Childhood Medulloblastoma: Results of Patients Treated in the Prospective Multicenter Trial HIT'91. Clinical Cancer Research, 2007, 13, 2651-2657.	7.0	90
148	Surgical management of pediatric brain tumors. Expert Review of Anticancer Therapy, 2007, 7, S61-S68.	2.4	20
149	Neurocognitive function in same-sex twins following focal radiation for medulloblastoma. Neuro-Oncology, 2007, 9, 460-464.	1.2	7
150	MMP-9 Short Interfering RNA Induced Senescence Resulting in Inhibition of Medulloblastoma Growth via p16INK4a and Mitogen-Activated Protein Kinase Pathway. Cancer Research, 2007, 67, 4956-4964.	0.9	53
151	Gain of 1q Is a Potential Univariate Negative Prognostic Marker for Survival in Medulloblastoma. Clinical Cancer Research, 2007, 13, 7022-7028.	7.0	36
152	Posterior Fossa Tumors in Children: Differential Diagnosis and Advanced Imaging Techniques. Neuroradiology Journal, 2007, 20, 449-460.	1.2	5
153	Feasibility and Toxicity of Intrathecal Liposomal Cytarabine in 5 Children and Young Adults With Refractory Neoplastic Meningitis. Journal of Pediatric Hematology/Oncology, 2007, 29, 222-226.	0.6	27
154	Survival among children with medulloblastoma in Greece: gains from transition to chemotherapy and socio-economic differentials. European Journal of Cancer Prevention, 2007, 16, 460-465.	1.3	3
155	Photonic explorers based on multifunctional nanoplatforms for biosensing and photodynamic therapy. Applied Optics, 2007, 46, 1924.	2.1	60

#	ARTICLE	IF	CITATIONS
156	Interferon- $\beta$ mediated up-regulation of caspase-8 sensitises medulloblastoma cells to radio- and chemotherapy. <i>European Journal of Cancer</i> , 2007, 43, 1833-1841.	2.8	32
157	Emerging Treatments and Gene Expression Profiling in High-Risk Medulloblastoma. <i>Paediatric Drugs</i> , 2007, 9, 81-96.	3.1	12
158	Temozolomide Treatment of an Adult with a Relapsing Medulloblastoma. <i>Cancer Investigation</i> , 2007, 25, 470-475.	1.3	21
159	Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 295-304.	4.3	175
160	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 839-851.	2.8	76
161	Long-term results of a prospective study on the treatment of medulloblastoma in adults. <i>Cancer</i> , 2007, 110, 2035-2041.	4.1	126
162	Common Strategy for Adult and Pediatric Medulloblastoma: A Multicenter Series of 253 Adults. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 433-440.	0.8	130
163	Timing of radiation in children with medulloblastoma/PNET. <i>Pediatric Blood and Cancer</i> , 2007, 48, 416-422.	1.5	4
164	High-dose chemotherapy and autologous stem cell rescue in children with newly diagnosed high-risk or relapsed medulloblastoma or supratentorial primitive neuroectodermal tumor. <i>Pediatric Blood and Cancer</i> , 2007, 48, 408-415.	1.5	67
165	Impact of telemedicine on pediatric neuro-oncology in a developing country: The Jordanian-Canadian experience. <i>Pediatric Blood and Cancer</i> , 2007, 48, 39-43.	1.5	83
166	Cerebellar leptomeningeal carcinomatosis in a dog. <i>Journal of Small Animal Practice</i> , 2007, 48, 504-507.	1.2	14
167	Medulloblastoma in childhood: new biological advances. <i>Lancet Neurology</i> , The, 2007, 6, 1073-1085.	10.2	239
168	Outcome of children with posterior fossa medulloblastoma: a single institution experience over the decade 1994-2003. <i>Child's Nervous System</i> , 2007, 23, 399-405.	1.1	27
169	Pilot study of ifosfamide/carboplatin/etoposide (ICE) for peripheral blood stem cell mobilization in patients with high-risk or relapsed medulloblastoma. <i>Child's Nervous System</i> , 2007, 23, 407-413.	1.1	10
170	Type I collagen is overexpressed in medulloblastoma as a component of tumor microenvironment. <i>Journal of Neuro-Oncology</i> , 2008, 86, 133-141.	2.9	51
171	The value of tandem CSF/MRI evaluation for predicting disseminated disease in childhood central nervous system neoplasms. <i>Journal of Neuro-Oncology</i> , 2008, 87, 97-102.	2.9	13
172	Medulloblastoma in children: a 32-year experience from a single institution. <i>Journal of Neuro-Oncology</i> , 2008, 90, 99-103.	2.9	20
173	M1 Medulloblastoma: high risk at any age. <i>Journal of Neuro-Oncology</i> , 2008, 90, 351-355.	2.9	27

#	ARTICLE	IF	CITATIONS
175	Accumulation of genomic aberrations during clinical progression of medulloblastoma. <i>Acta Neuropathologica</i> , 2008, 116, 383-390.	7.7	23
176	Characteristics and outcomes of medulloblastoma in adults. <i>Pediatric Blood and Cancer</i> , 2008, 51, 603-607.	1.5	45
177	Intraarterial chemotherapy and osmotic blood-brain barrier disruption for patients with embryonal and germ cell tumors of the central nervous system. <i>Cancer</i> , 2008, 112, 581-588.	4.1	54
178	Advances in the Management of Pediatric Central Nervous System Tumors. <i>Annals of the New York Academy of Sciences</i> , 2008, 1138, 22-31.	3.8	10
179	Role of Prognostic Factors in the Management of Pediatric Solid Tumors. <i>Annals of the New York Academy of Sciences</i> , 2008, 1138, 32-42.	3.8	4
180	Paratesticular metastases from a medulloblastoma. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2008, 4, 68-70.	1.1	0
181	Integrins mediate adhesion of medulloblastoma cells to tenascin and activate pathways associated with survival and proliferation. <i>Laboratory Investigation</i> , 2008, 88, 1143-1156.	3.7	52
182	Medulloblastoma: what is the role of molecular genetics?. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 1169-1181.	2.4	13
183	Chemotherapy for Malignant Brain Tumors of Childhood. <i>Journal of Child Neurology</i> , 2008, 23, 1149-1159.	1.4	85
186	Improvement in dose homogeneity with electronic tissue compensation over IMRT and conventional RT in whole brain radiotherapy. <i>Radiotherapy and Oncology</i> , 2008, 88, 196-201.	0.6	5
187	Low-dose Craniospinal Irradiation and Ifosfamide, Cisplatin and Etoposide for Non-metastatic Embryonal Tumors in the Central Nervous System. <i>Japanese Journal of Clinical Oncology</i> , 2008, 38, 486-492.	1.3	12
188	Medulloblastoma: new insights into biology and treatment. <i>Archives of Disease in Childhood: Education and Practice Edition</i> , 2008, 93, 137-144.	0.5	24
189	Therapeutic targets for medulloblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2008, 12, 449-461.	3.4	4
190	Histologic Features and Prognosis in Pediatric Medulloblastoma. <i>Pediatric and Developmental Pathology</i> , 2008, 11, 337-343.	1.0	19
191	MULTIVARIATE SURVIVAL ANALYSIS OF CHILDREN WITH MEDULLOBLASTOMA—A Single-Center Experience. <i>Pediatric Hematology and Oncology</i> , 2008, 25, 647-654.	0.8	1
192	Diagnostic and Therapeutic Stratification of Childhood Brain Tumors: Implications for Translational Research. <i>Journal of Child Neurology</i> , 2008, 23, 1179-1185.	1.4	8
193	Differential expression and prognostic significance of SOX genes in pediatric medulloblastoma and ependymoma identified by microarray analysis. <i>Neuro-Oncology</i> , 2008, 10, 648-660.	1.2	99
194	Medulloblastoma: From Molecular Pathology to Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 971-976.	7.0	149

#	ARTICLE	IF	CITATIONS
195	Expression of MAGE and GAGE genes in medulloblastoma and modulation of resistance to chemotherapy. <i>Journal of Neurosurgery: Pediatrics</i> , 2008, 1, 305-313.	1.3	40
196	Outcome in children with brain tumours diagnosed in the first year of life: long-term complications and quality of life. <i>Archives of Disease in Childhood</i> , 2008, 93, 582-589.	1.9	35
197	Different Treatment Strategies for Pediatric Brain Tumors. <i>Current Pediatric Reviews</i> , 2008, 4, 178-186.	0.8	0
198	Impact of Radiation Avoidance on Survival and Neurocognitive Outcome in Infant Medulloblastoma. <i>Current Oncology</i> , 2009, 16, 21-28.	2.2	65
199	Antiangiogenic Therapy in the Treatment of Recurrent Medulloblastoma in the Adult: Case Report and Review of the Literature. <i>Journal of Oncology</i> , 2009, 2009, 1-4.	1.3	13
200	Survival and prognostic factors in a series of adults with medulloblastomas. <i>Journal of Neurosurgery</i> , 2009, 111, 478-487.	1.6	51
201	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the <i>MYC</i> and <i>MYCN</i> Loci. <i>Journal of Clinical Oncology</i> , 2009, 27, 1627-1636.	1.6	274
203	Imatinib blocks migration and invasion of medulloblastoma cells by concurrently inhibiting activation of platelet-derived growth factor receptor and transactivation of epidermal growth factor receptor. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1137-1147.	4.1	55
204	Treatment of early childhood medulloblastoma by postoperative chemotherapy and deferred radiotherapy. <i>Neuro-Oncology</i> , 2009, 11, 201-210.	1.2	125
205	Hyperfractionated Accelerated Radiotherapy in the Milan Strategy for Metastatic Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 566-571.	1.6	140
206	Does diagnostic delay result in decreased survival in paediatric brain tumours?. <i>European Journal of Pediatrics</i> , 2009, 168, 303-310.	2.7	65
207	The follow-up of 34 children with medulloblastoma who received 3-dimensional conformal radiation therapy. <i>Chinese-German Journal of Clinical Oncology</i> , 2009, 8, 384-387.	0.1	0
208	A scoring system to quantify late effects in children after treatment for medulloblastoma/ependymoma and its correlation with quality of life and neurocognitive functioning. <i>Child's Nervous System</i> , 2009, 25, 173-181.	1.1	32
209	Medulloblastoma: clinicopathologic evaluation of 42 pediatric cases. <i>Child's Nervous System</i> , 2009, 25, 353-356.	1.1	11
210	A Phase II Study of Preradiotherapy Chemotherapy Followed by Hyperfractionated Radiotherapy for Newly Diagnosed High-Risk Medulloblastoma/Primitive Neuroectodermal Tumor: A Report From the Children's Oncology Group (CCG 9931). <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 74, 1006-1011.	0.8	47
211	Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics. <i>Journal of Pathology</i> , 2009, 218, 86-94.	4.5	171
212	Non-pineal supratentorial primitive neuroectodermal tumors (sPNET) in teenagers and young adults: Time to reconsider cisplatin based chemotherapy after cranio-spinal irradiation?. <i>Pediatric Blood and Cancer</i> , 2009, 52, 796-803.	1.5	18
213	Nutritional problems in children treated for medulloblastoma: Implications for enteral nutrition support. <i>Pediatric Blood and Cancer</i> , 2009, 53, 570-575.	1.5	29

#	ARTICLE	IF	CITATIONS
214	Is CSF cytology a useful diagnostic procedure in staging paediatric CNS tumours?. Cytopathology, 2009, 20, 256-260.	0.7	9
215	Small Solutions for Big Problems: The Application of Nanoparticles to Brain Tumor Diagnosis and Therapy. Clinical Pharmacology and Therapeutics, 2009, 85, 531-534.	4.7	89
216	Pediatric Brain Tumors: Current Treatment Strategies and Future Therapeutic Approaches. Neurotherapeutics, 2009, 6, 570-586.	4.4	141
217	Role of Rac1-regulated signaling in medulloblastoma invasion. Journal of Neurosurgery: Pediatrics, 2009, 4, 97-104.	1.3	17
218	Current Treatment Approaches for Infants with Malignant Central Nervous System Tumors. Oncologist, 2009, 14, 433-444.	3.7	55
219	Medulloblastoma. Journal of Child Neurology, 2009, 24, 1418-1430.	1.4	112
220	Pediatric medulloblastoma: Toxicity of current treatment and potential role of protontherapy. Cancer Treatment Reviews, 2009, 35, 79-96.	7.7	123
221	Long-term outcome and clinical prognostic factors in children with medulloblastoma treated in the prospective randomised multicentre trial HITâ€™91. European Journal of Cancer, 2009, 45, 1209-1217.	2.8	173
223	Treatment of Medulloblastoma with Hedgehog Pathway Inhibitor GDC-0449. New England Journal of Medicine, 2009, 361, 1173-1178.	27.0	951
224	The potential impact of tumour biology on improved clinical practice for medulloblastoma: progress towards biologically driven clinical trials. British Journal of Neurosurgery, 2009, 23, 364-375.	0.8	87
225	Targeting Myc in Pediatric Malignancies of the Central and Peripheral Nervous System. Current Cancer Drug Targets, 2009, 9, 176-188.	1.6	12
228	Childhood medulloblastoma: novel approaches to the classification of a heterogeneous disease. Acta Neuropathologica, 2010, 120, 305-316.	7.7	107
229	Molecular diagnostics of CNS embryonal tumors. Acta Neuropathologica, 2010, 120, 553-566.	7.7	83
230	A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma. Medical Oncology, 2010, 27, 985-991.	2.5	13
231	Evidence in medulloblastomas. Clinical and Translational Oncology, 2010, 12, 271-277.	2.4	4
232	Outcome and prognostic factors of desmoplastic medulloblastoma treated within a multidisciplinary treatment concept. BMC Cancer, 2010, 10, 450.	2.6	16
233	Incidence, Risks, and Sequelae of Posterior Fossa Syndrome in Pediatric Medulloblastoma. International Journal of Radiation Oncology Biology Physics, 2010, 77, 106-112.	0.8	99
234	Medulloblastoma in young children. Pediatric Blood and Cancer, 2010, 54, 635-637.	1.5	52

#	ARTICLE	IF	CITATIONS
235	Correlation between pre- or postoperative MRI findings and cerebellar sequelae in patients with medulloblastomas. <i>Pediatric Blood and Cancer</i> , 2010, 55, 1310-1316.	1.5	13
236	Notch signaling is not essential in sonic hedgehog-activated medulloblastoma. <i>Oncogene</i> , 2010, 29, 3865-3872.	5.9	24
237	The role of MMP-9 in the anti-angiogenic effect of secreted protein acidic and rich in cysteine. <i>British Journal of Cancer</i> , 2010, 102, 530-540.	6.4	36
238	Case 57 Cerebellar Medulloblastoma. , 2010, , .		0
239	Pediatric Neuro-Oncology. <i>Blue Books of Neurology</i> , 2010, , 150-200.	0.1	0
240	A Case of Relapsed Medulloblastoma Treated with Intensity-Modulated Radiotherapy and Temozolomide. <i>Tumori</i> , 2010, 96, 327-331.	1.1	5
241	Reduced-dose craniospinal radiotherapy followed by high-dose chemotherapy and autologous stem cell rescue for children with newly diagnosed high-risk medulloblastoma or supratentorial primitive neuroectodermal tumor. <i>The Korean Journal of Hematology</i> , 2010, 45, 120.	0.7	14
242	Multifunctional Nanoparticles for Targeted Imaging and Therapy of Cancer. <i>Materials Research Society Symposia Proceedings</i> , 2010, 1257, 1.	0.1	1
243	Survival and Prognostic Factors of Early Childhood Medulloblastoma: An International Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2010, 28, 4961-4968.	1.6	273
244	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.9	62
245	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. <i>Neurosurgical Focus</i> , 2010, 28, E6.	2.3	48
246	The Role of T-Helper 17 (Th17) Cells in Patients with Medulloblastoma. <i>Journal of International Medical Research</i> , 2010, 38, 611-619.	1.0	25
247	Pediatric CNS Tumors. <i>Pediatric Oncology</i> , 2010, , .	0.5	11
249	Recurrence in medulloblastoma – Influence of clinical, histological and immunohistochemical factors. <i>British Journal of Neurosurgery</i> , 2010, 24, 295-303.	0.8	9
250	Handbook of Evidence-Based Radiation Oncology. , 2010, , .		45
251	Possibilities of new therapeutic strategies in brain tumors. <i>Cancer Treatment Reviews</i> , 2010, 36, 335-341.	7.7	33
252	Review: Targeting the Hedgehog pathway in cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2010, 2, 237-250.	3.2	262
253	Childhood Medulloblastoma. <i>CNS Drugs</i> , 2010, 24, 285-301.	5.9	26

#	ARTICLE	IF	CITATIONS
254	Radiobiological risk estimates of adverse events and secondary cancer for proton and photon radiation therapy of pediatric medulloblastoma. <i>Acta Oncol</i> , 2011, 50, 806-816.	1.8	132
255	Medulloblastomas del adulto: serie quirúrgica de 11 casos. <i>Neurocirugia</i> , 2011, 22, 488-497.	0.4	1
256	Review and update about medulloblastoma in children. <i>Radiologia</i> , 2011, 53, 134-145.	0.5	9
257	Childhood brain tumors: epidemiology, current management and future directions. <i>Nature Reviews Neurology</i> , 2011, 7, 495-506.	10.1	110
258	Diseases. , 2011, , 189-348.		0
259	Hersentumoren op kinderleeftijd. <i>Tijdschrift Voor Kindergeneeskunde</i> , 2011, 79, 146-155.	0.0	0
261	Treatment of young children with localized medulloblastoma by chemotherapy alone: Results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology. <i>Neuro-Oncology</i> , 2011, 13, 669-679.	1.2	149
263	Outcome of medulloblastoma in children treated with reduced-dose radiation therapy plus adjuvant chemotherapy. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 515-519.	1.5	17
264	The tumor biology and molecular characteristics of medulloblastoma identifying prognostic factors associated with survival outcomes and prognosis. <i>Journal of Clinical Neuroscience</i> , 2011, 18, 886-890.	1.5	12
265	Meningiomas in children and adolescents: a meta-analysis of individual patient data. <i>Lancet Oncology</i> , 2011, 12, 1229-1239.	10.7	138
266	Disease Control and Ototoxicity Using Intensity-Modulated Radiation Therapy Tumor-Bed Boost for Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e15-e20.	0.8	42
267	Outcome and Prognostic Factors of Radiation Therapy for Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, e7-e13.	0.8	47
268	Chemotherapy of Medulloblastoma in Children. , 2011, , .		0
269	Malignant Brain Tumors in Childhood. , 0, , .		0
270	The Role of HGF/c-Met Pathway Signaling in Human Medulloblastoma. , 0, , .		3
271	Medulloblastomas in adults. <i>Current Opinion in Neurology</i> , 2011, 24, 626-632.	3.6	16
272	Medulloblastomas. <i>Current Opinion in Oncology</i> , 2011, 23, 630-637.	2.4	20
274	Recurrence in childhood medulloblastoma. <i>Journal of Neuro-Oncology</i> , 2011, 103, 705-711.	2.9	22



#	ARTICLE	IF	CITATIONS
275	Appraisal of the current staging system for residual medulloblastoma by volumetric analysis. Child's Nervous System, 2011, 27, 2101-2106.	1.1	6
276	The impact of provider surgical volumes on survival in children with primary tumors of the central nervous system—a population-based study. Acta Neurochirurgica, 2011, 153, 1219-1229.	1.7	15
277	TH1 predominance is associated with improved survival in pediatric medulloblastoma patients. Cancer Immunology, Immunotherapy, 2011, 60, 693-703.	4.2	23
278	Management of Childhood Brain Tumors: Consensus Report by the Pediatric Hematology Oncology (PHO) Chapter of Indian Academy of Pediatrics (IAP). Indian Journal of Pediatrics, 2011, 78, 1510-1519.	0.8	5
279	c-MYC expression sensitizes medulloblastoma cells to radio- and chemotherapy and has no impact on response in medulloblastoma patients. BMC Cancer, 2011, 11, 74.	2.6	22
280	Local control after craniospinal irradiation, intensity-modulated radiotherapy boost, and chemotherapy in childhood medulloblastoma. Cancer, 2011, 117, 635-641.	4.1	28
281	Childhood medulloblastoma. Critical Reviews in Oncology/Hematology, 2011, 79, 65-83.	4.4	58
282	SPARC Stimulates Neuronal Differentiation of Medulloblastoma Cells via the Notch1/STAT3 Pathway. Cancer Research, 2011, 71, 4908-4919.	0.9	43
283	Primary holocord ganglioneuroblastoma. Journal of Neurosurgery: Spine, 2011, 15, 457-463.	1.7	6
284	Embryonal Central Nervous System Neoplasms Arising in Infants and Young Children: A Pediatric Brain Tumor Consortium Study. Archives of Pathology and Laboratory Medicine, 2011, 135, 984-993.	2.5	18
285	Epigenetic mechanisms regulating neural development and pediatric brain tumor formation. Journal of Neurosurgery: Pediatrics, 2011, 8, 119-132.	1.3	12
286	Multidisciplinary management of childhood brain tumors: a review of outcomes, recent advances, and challenges. Journal of Neurosurgery: Pediatrics, 2011, 8, 135-148.	1.3	108
287	Cerebrospinal fluid M staging for medulloblastoma: Reappraisal of Chang's M staging based on the CSF flow. Neuro-Oncology, 2011, 13, 334-344.	1.2	14
288	Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma. Neuro-Oncology, 2011, 13, 376-383.	1.2	23
289	Chromosome 9q and 16q Loss Identified by Genome-Wide Pooled-Analysis Are Associated with Tumor Aggressiveness in Patients with Classic Medulloblastoma. OMICS A Journal of Integrative Biology, 2011, 15, 273-280.	2.0	7
290	Risk-adapted chemotherapy in childhood medulloblastoma. Expert Review of Anticancer Therapy, 2011, 11, 771-780.	2.4	8
291	The microtubule stabilizer patupilone (epothilone B) is a potent radiosensitizer in medulloblastoma cells. Neuro-Oncology, 2011, 13, 1000-1010.	1.2	32
292	EZH2-Regulated DAB2IP Is a Medulloblastoma Tumor Suppressor and a Positive Marker for Survival. Clinical Cancer Research, 2012, 18, 4048-4058.	7.0	76



#	ARTICLE	IF	CITATIONS
293	CSF and laboratory analysis (tumor markers). Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 104, 143-148.	1.8	6
294	Ataxia resulting from posterior fossa tumors of childhood and other mass lesions. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 103, 161-173.	1.8	4
295	Early recurrence in standard-risk medulloblastoma patients with the common idic(17)(p11.2) rearrangement. Neuro-Oncology, 2012, 14, 831-840.	1.2	13
296	Hyperfractionated Versus Conventional Radiotherapy Followed by Chemotherapy in Standard-Risk Medulloblastoma: Results From the Randomized Multicenter HIT-SIOP PNET 4 Trial. Journal of Clinical Oncology, 2012, 30, 3187-3193.	1.6	270
297	Posterior Fossa Tumors in the Pediatric Population. , 2012, , 654-668.		1
299	Metastatic Medulloblastoma in Childhood: Chang's Classification Revisited. International Journal of Surgical Oncology, 2012, 2012, 1-6.	0.6	34
300	Medulloblastoma Model. Neuromethods, 2012, , 83-140.	0.3	0
302	Action of db-cAMP on the bystander effect and chemosensitivity through connexin 43 and Bcl-2-mediated pathways in medulloblastoma cells. Oncology Reports, 2012, 28, 969-976.	2.6	10
303	Matching mice to malignancy: molecular subgroups and models of medulloblastoma. Child's Nervous System, 2012, 28, 521-532.	1.1	19
304	Necrosis After Craniospinal Irradiation: Results From a Prospective Series of Children With Central Nervous System Embryonal Tumors. International Journal of Radiation Oncology Biology Physics, 2012, 83, e655-e660.	0.8	59
305	Oncolytic measles virus prolongs survival in a murine model of cerebral spinal fluid-disseminated medulloblastoma. Neuro-Oncology, 2012, 14, 459-470.	1.2	35
306	Brain Tumors in Children. Current Problems in Pediatric and Adolescent Health Care, 2012, 42, 80-103.	1.7	53
307	Concurrent cyclophosphamide and craniospinal radiotherapy for pediatric high-risk embryonal brain tumors. Journal of Neuro-Oncology, 2012, 110, 287-291.	2.9	5
308	Prognostic value of the TP53 Arg72Pro single-nucleotide polymorphism and susceptibility to medulloblastoma in a cohort of Brazilian patients. Journal of Neuro-Oncology, 2012, 110, 49-57.	2.9	10
309	A long duration of the prediagnostic symptomatic interval is not associated with an unfavourable prognosis in childhood medulloblastoma. European Journal of Cancer, 2012, 48, 2028-2036.	2.8	16
310	Early Childhood Medulloblastoma: Prognostic Factors. Pediatric Cancer, 2012, , 173-181.	0.0	0
311	Medulloblastoma and primitive neuroectodermal tumors. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2012, 105, 529-548.	1.8	38
312	Pediatric Brain Tumors (An Overview). Pediatric Cancer, 2012, , 61-73.	0.0	0

#	ARTICLE	IF	CITATIONS
313	Identification of Cell Surface Targets through Meta-analysis of Microarray Data. Neoplasia, 2012, 14, 666-669.	5.3	17
314	Medulloblastoma/Primitive Neuroectodermal Tumor and Germ Cell Tumors. Hematology/Oncology Clinics of North America, 2012, 26, 881-895.	2.2	5
315	Pediatric Cancer, Volume 3. Pediatric Cancer, 2012, , .	0.0	1
317	Clinical trials and chemotherapy. , 2012, , 306-315.		0
318	High-dose chemotherapy and autologous stem cell transplantation for pediatric brain tumors. Journal of the Korean Medical Association, 2012, 55, 430.	0.3	2
319	Medulloblastoma and primitive neuroectodermal tumors. , 2012, , 503-517.		0
320	The role of chemotherapy in the treatment of pediatric brain tumors. Journal of the Korean Medical Association, 2012, 55, 420.	0.3	1
321	Outcome of Children With Metastatic Medulloblastoma Treated With Carboplatin During Craniospinal Radiotherapy: A Children's Oncology Group Phase I/II Study. Journal of Clinical Oncology, 2012, 30, 2648-2653.	1.6	166
322	Medulloblastoma: challenges for effective immunotherapy. Journal of Neuro-Oncology, 2012, 108, 1-10.	2.9	26
323	Medulloblastoma. Current Treatment Options in Neurology, 2012, 14, 416-426.	1.8	38
324	Identification of c-myc-dependent proteins in the medulloblastoma cell line D425Med. Amino Acids, 2012, 42, 2149-2163.	2.7	7
325	Medulloblastoma: Progress over time. Journal of Medical Imaging and Radiation Oncology, 2012, 56, 227-234.	1.8	11
326	Relative survival of childhood and adult medulloblastomas and primitive neuroectodermal tumors (PNETs). Cancer, 2012, 118, 1313-1322.	4.1	93
327	p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease. Journal of Neuro-Oncology, 2012, 106, 135-141.	2.9	28
328	Adult medulloblastoma: multiagent chemotherapy with cisplatin and etoposide: a single institutional experience. Journal of Neuro-Oncology, 2012, 106, 595-600.	2.9	20
329	ID3 contributes to cerebrospinal fluid seeding and poor prognosis in medulloblastoma. BMC Cancer, 2013, 13, 291.	2.6	19
330	Pediatric Cancer, Volume 4. Pediatric Cancer, 2013, , .	0.0	0
331	Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's Nervous System, 2013, 29, 589-596.	1.1	66

#	ARTICLE	IF	CITATIONS
332	The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2013, 1, 19.	5.2	26
333	The Role of microRNAs in Medulloblastoma. <i>Pediatric Hematology and Oncology</i> , 2013, 30, 367-378.	0.8	15
334	High-Risk Medulloblastoma: A Pediatric Oncology Group Randomized Trial of Chemotherapy Before or After Radiation Therapy (POG 9031). <i>Journal of Clinical Oncology</i> , 2013, 31, 2936-2941.	1.6	132
335	Central nervous system tumors. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2013, 112, 931-958.	1.8	13
336	Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. <i>Neuro-Oncology</i> , 2013, 15, 97-103.	1.2	212
337	Treatment Options for Medulloblastoma and CNS Primitive Neuroectodermal Tumor (PNET). <i>Current Treatment Options in Neurology</i> , 2013, 15, 593-606.	1.8	47
339	Medulloblastoma. <i>Clinical Oncology</i> , 2013, 25, 36-45.	1.4	70
340	Treatment of adult nonmetastatic medulloblastoma patients according to the paediatric HIT 2000 protocol: A prospective observational multicentre study. <i>European Journal of Cancer</i> , 2013, 49, 893-903.	2.8	84
341	Medulloblastoma: recurrence and metastasis. <i>CNS Oncology</i> , 2013, 2, 377-385.	3.0	28
342	Pulmonary Hypertensive Vasculopathy Following Tandem Autologous Transplantation in Pediatric Patients with Central Nervous System Tumors. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 235-239.	2.0	12
343	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	1.1	12
344	Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma. <i>Neuro-Oncology</i> , 2013, 15, 352-359.	1.2	33
345	Medulloblastoma invading the transverse sinus. <i>Journal of Neurosurgery: Pediatrics</i> , 2013, 12, 325-327.	1.3	1
346	Expression of miR-124 inhibits growth of medulloblastoma cells. <i>Neuro-Oncology</i> , 2013, 15, 83-90.	1.2	59
347	Treatment options for childhood medulloblastoma. <i>Vojnosanitetski Pregled</i> , 2013, 70, 773-777.	0.2	3
348	Local perspective on a rare brain tumour: adult medulloblastoma. <i>Internal Medicine Journal</i> , 2013, 43, 567-572.	0.8	9
349	Local control in non-metastatic medulloblastoma. <i>Acta Oncologica</i> , 2014, 53, 1151-1157.	1.8	6
350	The impact of recent vincristine on human hematopoietic progenitor cell collection in pediatric patients with central nervous system tumors. <i>Transfusion</i> , 2014, 54, 2004-2014.	1.6	4

#	ARTICLE	IF	CITATIONS
351	Netrin-1 Promotes Medulloblastoma Cell Invasiveness and Angiogenesis, and Demonstrates Elevated Expression in Tumor Tissue and Urine of Patients with Pediatric Medulloblastoma. <i>Cancer Research</i> , 2014, 74, 3716-3726.	0.9	53
352	Overcoming multiple drug resistance mechanisms in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 57.	5.2	49
353	Treatment outcomes and late toxicities in patients with embryonal central nervous system tumors. <i>Radiation Oncology</i> , 2014, 9, 201.	2.7	11
355	Pediatric Hematology-Oncology in Countries with Limited Resources. , 2014, , .		7
356	The rationale for targeted therapies in medulloblastoma. <i>Neuro-Oncology</i> , 2014, 16, 9-20.	1.2	54
357	Treatment developments and the unfolding of the quality of life discussion in childhood medulloblastoma: a review. <i>Child's Nervous System</i> , 2014, 30, 979-990.	1.1	41
358	Fluorescence-guided surgery with 5-aminolevulinic acid for resection of brain tumors in childrenâ€”a technical report. <i>Acta Neurochirurgica</i> , 2014, 156, 597-604.	1.7	46
359	Chemotherapy in Childhood Brain Tumors. <i>Current Pediatrics Reports</i> , 2014, 2, 38-49.	4.0	5
360	Hyperfractionated Accelerated Radiotherapy (HART) with maintenance chemotherapy for metastatic (M1â€“3) Medulloblastoma â€” A safety/feasibility study. <i>Radiotherapy and Oncology</i> , 2014, 111, 41-46.	0.6	9
361	Tandem highâ€”dose chemotherapy and autologous stem cell rescue in children with newly diagnosed highâ€”risk medulloblastoma or supratentorial primitive neuroâ€”ectodermic tumors. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1398-1402.	1.5	46
362	MYCN amplification predicts poor outcome for patients with supratentorial primitive neuroectodermal tumors of the central nervous system. <i>Neuro-Oncology</i> , 2014, 16, 924-932.	1.2	16
363	Highâ€”dose busulfanâ€”thiotepa with autologous stem cell transplantation followed by posterior fossa irradiation in young children with classical or incompletely resected medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 907-912.	1.5	18
364	Recent developments and current concepts in medulloblastoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 356-365.	7.7	87
365	Management of Pediatric and Adult Patients with Medulloblastoma. <i>Current Treatment Options in Oncology</i> , 2014, 15, 581-594.	3.0	82
366	Dasatinib suppression of medulloblastoma survival and migration is markedly enhanced by combining treatment with the aurora kinase inhibitor AT9283. <i>Cancer Letters</i> , 2014, 354, 68-76.	7.2	16
367	Apparent diffusion coefficient in glioblastoma with PNET-like components, a GBM variant. <i>Journal of Neuro-Oncology</i> , 2014, 119, 353-360.	2.9	19
368	Management Paradigms Along a Histologic Spectrum of Pineal Cell Tumors. <i>World Neurosurgery</i> , 2014, 81, 685-687.	1.3	3
369	Goldenhar syndrome and medulloblastoma: A coincidental association? The first case report. <i>Journal of Cranio-Maxillo-Facial Surgery</i> , 2014, 42, e91-e96.	1.7	3

#	ARTICLE	IF	CITATIONS
370	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	16.8	241
371	miR-219 inhibits the proliferation, migration and invasion of medulloblastoma cells by targeting CD164. <i>International Journal of Molecular Medicine</i> , 2014, 34, 237-243.	4.0	29
372	Advances in managing medulloblastoma and intracranial primitive neuro-ectodermal tumors. <i>F1000prime Reports</i> , 2014, 6, 56.	5.9	13
373	Current outcome predictors in childhood primitive neuroectodermal tumors. <i>Journal of Pediatric Neurology</i> , 2015, 01, 075-082.	0.2	1
374	Clinical Insights: Optimal Therapy of Pediatric Medulloblastoma. , 2015, , .		0
375	Acute toxicity profile of craniospinal irradiation with intensity-modulated radiation therapy in children with medulloblastoma: A prospective analysis. <i>Radiation Oncology</i> , 2015, 10, 241.	2.7	24
376	Long-term life expectancy for children with ependymoma and medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1986-1991.	1.5	10
377	The UK Experience of a Treatment Strategy for Pediatric Metastatic Medulloblastoma Comprising Intensive Induction Chemotherapy, Hyperfractionated Accelerated Radiotherapy and Response Directed High Dose Myeloablative Chemotherapy or Maintenance Chemothera. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2132-2139.	1.5	21
378	The Ketogenic Diet Does Not Affect Growth of Hedgehog Pathway Medulloblastoma in Mice. <i>PLoS ONE</i> , 2015, 10, e0133633.	2.5	30
379	Medulloblastoma: Pathology. , 2015, , 333-347.		0
381	Childhood medulloblastoma: current and future treatment strategies. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1299-1317.	0.8	2
382	Chemotherapy for children with medulloblastoma. <i>The Cochrane Library</i> , 2015, 2015, CD006678.	2.8	23
384	Embryonic Stem Cell-Related Protein L1TD1 Is Required for Cell Viability, Neurosphere Formation, and Chemoresistance in Medulloblastoma. <i>Stem Cells and Development</i> , 2015, 24, 2700-2708.	2.1	10
385	Meningiomas of the Pediatric Skull Base: A Review. <i>Journal of Neurological Surgery, Part B: Skull Base</i> , 2015, 76, 066-073.	0.8	25
386	Adult medulloblastoma: clinical characters, prognostic factors, outcomes and patterns of relapse. <i>Journal of Neuro-Oncology</i> , 2015, 124, 255-264.	2.9	25
387	High-dose Chemotherapy With Autologous Stem Cell Rescue in Saudi Children Less Than 3 Years of Age With Embryonal Brain Tumors. <i>Journal of Pediatric Hematology/Oncology</i> , 2015, 37, 204-208.	0.6	4
388	Imaging of pediatric cerebellar tumors. <i>Journal of Pediatric Neuroradiology</i> , 2015, 01, 081-094.	0.1	0
390	Smoothed Inhibitors in Sonic Hedgehog Subgroup Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 2692-2694.	1.6	12

#	ARTICLE	IF	CITATIONS
391	Metastatic medulloblastoma in adults: Outcome of patients treated according to the HIT2000 protocol. <i>European Journal of Cancer</i> , 2015, 51, 2434-2443.	2.8	30
392	Intraventricular methotrexate as part of primary therapy for children with infant and/or metastatic medulloblastoma: Feasibility, acute toxicity and evidence for efficacy. <i>European Journal of Cancer</i> , 2015, 51, 2634-2642.	2.8	44
393	Factors affecting survival of medulloblastoma in children: the changing concept of management. <i>Child's Nervous System</i> , 2015, 31, 1687-1698.	1.1	18
394	Extraneural metastases of medulloblastoma: Desmoplastic variants may have prolonged survival. <i>Pediatric Blood and Cancer</i> , 2015, 62, 611-615.	1.5	11
395	Brain Tumors. <i>Pediatric Clinics of North America</i> , 2015, 62, 167-178.	1.8	40
396	Childhood medulloblastoma. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 105, 35-51.	4.4	119
397	High Incidence of Venous Occlusive Disease With Myeloablative Chemotherapy Following Craniospinal Irradiation in Children With Newly Diagnosed High-Risk CNS Embryonal Tumors: A Report From the Children's Oncology Group (COG P99702). <i>Pediatric Blood and Cancer</i> , 2016, 63, 1563-1570.	1.5	13
398	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	7.8	58
399	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478
400	Paediatric cancer stage in population-based cancer registries: the Toronto consensus principles and guidelines. <i>Lancet Oncology</i> , The, 2016, 17, e163-e172.	10.7	56
401	Free-Breathing Radial 3D Fat-Suppressed T1-Weighted Gradient-Echo Sequence for Contrast-Enhanced Pediatric Spinal Imaging: Comparison With T1-Weighted Turbo Spin-Echo Sequence. <i>American Journal of Roentgenology</i> , 2016, 207, 177-182.	2.2	17
402	Spinal Cord Tumors. , 2016, , 521-540.e5.		3
403	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. <i>Journal of Clinical Oncology</i> , 2016, 34, 4151-4160.	1.6	121
404	CAT3, a novel agent for medulloblastoma and glioblastoma treatment, inhibits tumor growth by disrupting the Hedgehog signaling pathway. <i>Cancer Letters</i> , 2016, 381, 391-403.	7.2	25
405	Postoperative Radiotherapy Patterns of Care and Survival Implications for Medulloblastoma in Young Children. <i>JAMA Oncology</i> , 2016, 2, 1574.	7.1	47
406	Adjuvant chemotherapy and overall survival in adult medulloblastoma. <i>Neuro-Oncology</i> , 2017, 19, now150.	1.2	38
407	Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFN- $\gamma$ Rko Mice. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 145-151.	3.1	9
408	Late effects of craniospinal irradiation for standard risk medulloblastoma in paediatric patients: A comparison of treatment techniques. <i>Radiography</i> , 2016, 22, S52-S56.	2.1	1

#	ARTICLE	IF	CITATIONS
409	Electroretinography and Visual Evoked Potentials in Childhood Brain Tumor Survivors. <i>Journal of Child Neurology</i> , 2016, 31, 998-1004.	1.4	3
410	MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-properties. <i>BMC Cancer</i> , 2016, 16, 115.	2.6	17
412	Craniospinal irradiation with concomitant and adjuvant temozolomide—a feasibility assessment of toxicity in patients with glioblastoma with a PNET component. <i>Journal of Neuro-Oncology</i> , 2016, 127, 295-302.	2.9	8
413	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
414	p53 and Medulloblastoma. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2016, 6, a026278.	6.2	29
415	Central Nervous System Tumors in Children. , 2016, , 1389-1402.e3.		2
416	Establishment of a novel human medulloblastoma cell line characterized by highly aggressive stem-like cells. <i>Cytotechnology</i> , 2016, 68, 1545-1560.	1.6	15
417	Medulloblastoma. <i>Journal of Child Neurology</i> , 2016, 31, 1341-1353.	1.4	171
419	Large cell/anaplastic medulloblastoma is associated with poor prognosis—a retrospective analysis at a single institute. <i>Child's Nervous System</i> , 2017, 33, 1285-1294.	1.1	13
420	Tailoring Medulloblastoma Treatment Through Genomics: Making a Change, One Subgroup at a Time. <i>Annual Review of Genomics and Human Genetics</i> , 2017, 18, 143-166.	6.2	24
421	Beyond Correlations, Sensitivities, and Specificities. <i>Academic Radiology</i> , 2017, 24, 1036-1049.	2.5	9
422	Embryonal tumors in Canadian children less than 36 months of age: results from the Canadian Pediatric Brain Tumor Consortium (CPBTC). <i>Journal of Neuro-Oncology</i> , 2017, 133, 581-587.	2.9	3
423	Treatment of pediatric average-risk medulloblastoma using craniospinal irradiation less than 2500 cGy and chemotherapy: single center experience in Korea. <i>World Journal of Pediatrics</i> , 2017, 13, 367-373.	1.8	3
424	Proteomic profiling of isogenic primary and metastatic medulloblastoma cell lines reveals differential expression of key metastatic factors. <i>Journal of Proteomics</i> , 2017, 160, 55-63.	2.4	6
425	Outcome for children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor (CNS-PNET) — a retrospective analysis spanning 40 years of treatment. <i>Acta Oncologica</i> , 2017, 56, 698-705.	1.8	29
427	A Phase II feasibility study of oral etoposide given concurrently with radiotherapy followed by dose intensive adjuvant chemotherapy for children with newly diagnosed high-risk medulloblastoma (protocol POG 9631): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26373.	1.5	25
428	Posterior fossa syndrome and long-term neuropsychological outcomes among children treated for medulloblastoma on a multi-institutional, prospective study. <i>Neuro-Oncology</i> , 2017, 19, 1673-1682.	1.2	68
429	Growth impairment and gonadal axis abnormalities are common in survivors of paediatric brain tumours. <i>Acta Paediatrica, International Journal of Paediatrics</i> , 2017, 106, 1684-1693.	1.5	5



#	ARTICLE	IF	CITATIONS
430	Pediatric Medulloblastoma: a Case of Recurrent Disease and Resiliency. Journal of Pediatric Neuropsychology, 2017, 3, 136-155.	0.6	0
432	Embryonal Tumors. Pediatric Oncology, 2017, , 93-120.	0.5	0
433	Medulloblastomaâ†. , 2017, , .		0
434	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.6	22
435	Medulloblastoma: From Myth to Molecular. Journal of Clinical Oncology, 2017, 35, 2355-2363.	1.6	129
436	Factors Affecting the Prognosis of Children with Medulloblastoma: A Single Institution Retrospective Analysis of 40 Cases. Translational Neuroscience and Clinics, 2017, 3, 16-27.	0.1	4
437	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 753-763.	3.8	9
438	Agreement between gamma passing rates using computed tomography in radiotherapy and secondary cancer risk prediction from more advanced dose calculated models. Quantitative Imaging in Medicine and Surgery, 2017, 7, 292-298.	2.0	1
439	Targeting metabotropic glutamate receptors in the treatment of primary brain tumors. Current Opinion in Pharmacology, 2018, 38, 59-64.	3.5	4
440	Medulloblastoma: From Molecular Subgroups to Molecular Targeted Therapies. Annual Review of Neuroscience, 2018, 41, 207-232.	10.7	85
442	Brainstem Injury in Pediatric Patients With Posterior Fossa Tumors Treated With Proton Beam Therapy and Associated Dosimetric Factors. International Journal of Radiation Oncology Biology Physics, 2018, 100, 719-729.	0.8	55
443	Survival impact of postoperative radiotherapy timing in pediatric and adolescent medulloblastoma. Neuro-Oncology, 2018, 20, 1133-1141.	1.2	20
444	Zika Virus Selectively Kills Aggressive Human Embryonal CNS Tumor Cells <i>In Vitro</i> and <i>In Vivo</i>. Cancer Research, 2018, 78, 3363-3374.	0.9	54
445	Posterior fossa medulloblastoma in an atypical extra-axial location: A case report. Radiology Case Reports, 2018, 13, 365-370.	0.6	5
446	MRI Characteristics of Primary Tumors and Metastatic Lesions in Molecular Subgroups of Pediatric Medulloblastoma: A Single-Center Study. American Journal of Neuroradiology, 2018, 39, 949-955.	2.4	27
447	Preradiation Chemotherapy for Adult High-risk Medulloblastoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2018, 41, 588-594.	1.3	17
448	Long-term outcomes of adult medulloblastoma patients treated with radiotherapy. Journal of Neuro-Oncology, 2018, 136, 95-104.	2.9	26
449	Differential patterns of metastatic dissemination across medulloblastoma subgroups. Journal of Neurosurgery: Pediatrics, 2018, 21, 145-152.	1.3	39



#	ARTICLE	IF	CITATIONS
450	Cardiac Toxicity After Craniospinal Irradiation: A Late Effect That May be Eliminated With Proton Therapy. <i>Journal of Pediatric Hematology/Oncology</i> , 2018, 40, e330-e333.	0.6	6
452	Semaphorin 3F and Netrin-1: The Novel Function as a Regulator of Tumor Microenvironment. <i>Frontiers in Physiology</i> , 2018, 9, 1662.	2.8	12
453	20 Posterior Fossa Tumors. , 2018, , .		0
454	Accumulation of protoporphyrin IX in medulloblastoma cell lines and sensitivity to subsequent photodynamic treatment. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2018, 189, 298-305.	3.8	16
455	Pediatric Brain Tumor Genetics: What Radiologists Need to Know. <i>Radiographics</i> , 2018, 38, 2102-2122.	3.3	75
456	Childhood Medulloblastoma Revisited. <i>Topics in Magnetic Resonance Imaging</i> , 2018, 27, 479-502.	1.2	10
458	Cognitive Late Effects and Their Management. , 2018, , 317-345.		0
459	Principles of Radiation Oncology. , 2018, , 33-64.		2
460	Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. <i>Nature Communications</i> , 2018, 9, 4121.	12.8	36
462	The clinical importance of medulloblastoma extent of resection: a systematic review. <i>Journal of Neuro-Oncology</i> , 2018, 139, 523-539.	2.9	43
463	Chemotherapy for Medulloblastoma in Adults. , 2018, , 469-482.		0
464	Time to diagnosis of pediatric brain tumors: a report from the Pediatric Hematology and Oncology Center in Rabat, Morocco. <i>Child's Nervous System</i> , 2018, 34, 2431-2440.	1.1	10
465	Clinical and pre-clinical utility of genomics in medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2018, 18, 633-647.	2.8	13
467	A novel and practical synthesis of CAT3: a phenanthroindolizidine alkaloid with potential in treating glioblastoma. <i>RSC Advances</i> , 2018, 8, 29301-29308.	3.6	9
468	Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?. <i>Child's Nervous System</i> , 2018, 34, 1657-1662.	1.1	0
469	Embryonal Tumors. , 2018, , 1-17.		0
470	Cerebellar mutism syndrome. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 155, 273-288.	1.8	36
471	Nomograms based on preoperative multiparametric magnetic resonance imaging for prediction of molecular subgrouping in medulloblastoma: results from a radiogenomics study of 111 patients. <i>Neuro-Oncology</i> , 2019, 21, 115-124.	1.2	49

#	ARTICLE	IF	CITATIONS
472	Surgical resection of medulloblastoma: How much is sufficient and necessary? A systematic review of literature. Cancer Reports, 2019, 2, .	1.4	0
473	Medulloblastomas in cerebellopontine angle: Epidemiology, clinical manifestations, imaging features, molecular analysis and surgical outcome. Journal of Clinical Neuroscience, 2019, 67, 93-98.	1.5	9
474	Prognostic significance of molecular subgroups of medulloblastoma in young children receiving irradiation-sparing regimens. Journal of Neuro-Oncology, 2019, 145, 375-383.	2.9	7
475	Functional Outcomes of Cerebellar Malformations. Frontiers in Cellular Neuroscience, 2019, 13, 441.	3.7	35
476	Medulloblastoma: Distinctive Histo-Molecular Correlation with Clinical Profile, Radiologic Characteristics, and Surgical Outcome. Pediatric Neurosurgery, 2019, 54, 329-340.	0.7	11
477	Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1034-1042.	0.8	16
478	Adult medulloblastoma: an overview on current and future strategies of treatment. Expert Opinion on Orphan Drugs, 2019, 7, 383-389.	0.8	2
479	<p>Medulloblastoma: optimizing care with a multidisciplinary approach</p>. Journal of Multidisciplinary Healthcare, 2019, Volume 12, 335-347.	2.7	47
480	Principles of tumorigenesis and emerging molecular drivers of SHH -activated medulloblastomas. Annals of Clinical and Translational Neurology, 2019, 6, 990-1005.	3.7	17
481	The Role of Precision Medicine in the Diagnosis and Treatment of Patients with Rare Cancers. Cancer Treatment and Research, 2019, 178, 81-108.	0.5	2
482	Paediatric Neuro-Oncology: Medulloblastoma. , 2019, , 133-146.		0
483	Physician's Field Guide to Neuropsychology. , 2019, , .		2
484	Molecular markers and potential therapeutic targets in non-WNT/non-SHH (group 3 and group 4) medulloblastomas. Journal of Hematology and Oncology, 2019, 12, 29.	17.0	41
485	Pediatrics Cancers. , 2019, , 29-81.		0
486	Polyamine Metabolism as a Therapeutic Target in Hedgehog-Driven Basal Cell Carcinoma and Medulloblastoma. Cells, 2019, 8, 150.	4.1	17
487	Hematopoietic Cell Transplantation for Pediatric Solid Tumors. , 2019, , 289-299.		0
488	EANO-EURACAN clinical practice guideline for diagnosis, treatment, and follow-up of post-pubertal and adult patients with medulloblastoma. Lancet Oncology, The, 2019, 20, e715-e728.	10.7	56
489	Current Status and Future Prospects in the Field of Pediatric Tumors. Japanese Journal of Neurosurgery, 2019, 28, 211-219.	0.0	0

#	ARTICLE	IF	CITATIONS
490	Delays in Diagnosis of Pediatric Histologically Confirmed Sellar Germ Cell Tumors in China: A Retrospective Risk Factor Analysis. <i>World Neurosurgery</i> , 2019, 122, e472-e479.	1.3	13
491	A little piece of mind: best practices for brain tumor intraoperative consultation. <i>Modern Pathology</i> , 2019, 32, 44-57.	5.5	10
492	Medulloblastoma: Challenges and advances in treatment and research. <i>Cancer Reports</i> , 2019, 2, .	1.4	4
493	Complications of Posterior Fossa Tumors. , 2019, , 148-159.		0
494	Reoperation for Medulloblastoma Prior to Adjuvant Therapy. <i>Neurosurgery</i> , 2019, 84, 1050-1058.	1.1	7
495	Strategy to minimize radiation burden in infants and high-risk medulloblastoma using intrathecal methotrexate and high-dose chemotherapy: A prospective registry study in Japan. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28012.	1.5	9
496	Reduced-volume tumor-bed boost is not associated with inferior local control and survival outcomes in high-risk medulloblastoma. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28027.	1.5	3
497	Pediatric embryonal brain tumors in the molecular era. <i>Expert Review of Molecular Diagnostics</i> , 2020, 20, 293-303.	3.1	6
498	Cancer of the Central Nervous System. , 2020, , 906-967.e12.		9
499	5-Aminolevulinic Acid-Guided Surgery for Recurrent Supratentorial Pediatric Neoplasms. <i>World Neurosurgery</i> , 2020, 141, e763-e769.	1.3	5
500	Prolongation of radiotherapy duration is associated with inferior overall survival in patients with pediatric medulloblastoma and central nervous system primitive neuroectodermal tumors. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28558.	1.5	7
501	Evaluation of Prognostic Factors and Role of Participation in a Randomized Trial or a Prospective Registry in Pediatric and Adolescent Nonmetastatic Medulloblastoma – A Report From the HIT 2000 Trial. <i>Advances in Radiation Oncology</i> , 2020, 5, 1158-1169.	1.2	13
502	Pretreatment central quality control for craniospinal irradiation in non-metastatic medulloblastoma. <i>Strahlentherapie Und Onkologie</i> , 2021, 197, 674-682.	2.0	16
503	Paediatric posterior fossa tumour resection rates in a small volume centre: the past decade's experience. <i>British Journal of Neurosurgery</i> , 2021, 35, 451-455.	0.8	5
504	<p></p>Immunotherapy for Medulloblastoma: Current Perspectives</p>. <i>ImmunoTargets and Therapy</i> , 2020, Volume 9, 57-77.	5.8	33
505	ApoE mimetic peptide targeted nanoparticles carrying a BRD4 inhibitor for treating Medulloblastoma in mice. <i>Journal of Controlled Release</i> , 2020, 323, 463-474.	9.9	30
506	Pediatric Posterior Fossa Medulloblastoma: The Role of Diffusion Imaging in Identifying Molecular Groups. <i>Journal of Neuroimaging</i> , 2020, 30, 503-511.	2.0	9
507	Molecular-Clinical Correlation in Pediatric Medulloblastoma: A Cohort Series Study of 52 Cases in Taiwan. <i>Cancers</i> , 2020, 12, 653.	3.7	8

#	ARTICLE	IF	CITATIONS
508	Salvage therapy for progressive, treatment-refractory or recurrent pediatric medulloblastoma: a systematic review protocol. <i>Systematic Reviews</i> , 2020, 9, 47.	5.3	4
509	Promising survival rate but high incidence of treatmentâ€related mortality after reducedâ€dose craniospinal radiotherapy and tandem highâ€dose chemotherapy in patients with highâ€risk medulloblastoma. <i>Cancer Medicine</i> , 2020, 9, 5807-5818.	2.8	7
510	Simultaneous determination of a promising anti-brain tumor agent CAT3 and its two major metabolites in mouse plasma and brain by a LC-MS/MS method. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 181, 113106.	2.8	0
511	Preclinical Models of Craniospinal Irradiation for Medulloblastoma. <i>Cancers</i> , 2020, 12, 133.	3.7	4
512	Role of neoadjuvant chemotherapy in metastatic medulloblastoma: a comparative study in 92 children. <i>Neuro-Oncology</i> , 2020, 22, 1686-1695.	1.2	14
513	Medulloblastoma: A turning point from fundamental advances to improved survival and decreased sequelae. <i>Neurochirurgie</i> , 2021, 67, 3-5.	1.2	1
514	Surgical approach to the posterior fossa in children, including anesthetic considerations and complications: The prone and the sitting position. Technical note. <i>Neurochirurgie</i> , 2021, 67, 46-51.	1.2	5
515	A case of medulloblastoma in a patient with fetal ventricular enlargement. <i>Child's Nervous System</i> , 2021, 37, 977-982.	1.1	0
516	Real-world data for pediatric medulloblastoma: can we improve outcomes?. <i>European Journal of Pediatrics</i> , 2021, 180, 127-136.	2.7	8
517	Medulloblastomas in adolescents and adults â€ Can the pediatric experience be extrapolated?. <i>Neurochirurgie</i> , 2021, 67, 76-82.	1.2	7
518	<scp>3D</scp> hydrogels reveal medulloblastoma subgroup differences and identify extracellular matrix subtypes that predict patient outcome. <i>Journal of Pathology</i> , 2021, 253, 326-338.	4.5	6
519	A Multi-institutional Comparative Analysis of Proton and Photon Therapy-Induced Hematologic Toxicity in Patients With Medulloblastoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 726-735.	0.8	29
520	Benign skull and subdural lesions in patients with prior medulloblastoma therapy. <i>Child's Nervous System</i> , 2021, 37, 359-366.	1.1	1
521	Management of high-risk medulloblastoma. <i>Neurochirurgie</i> , 2021, 67, 61-68.	1.2	15
522	Evaluation of an infratentorial lesion. , 2021, , 81-92.		0
523	Safety and efficacy of concurrent carboplatin during fullâ€dose craniospinal irradiation for highâ€risk/metastatic medulloblastoma in a resourceâ€limited setting. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28925.	1.5	6
524	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44
525	Surgical management of posterior fossa medulloblastoma in children: The Lyon experience. <i>Neurochirurgie</i> , 2021, 67, 52-60.	1.2	5

#	ARTICLE	IF	CITATIONS
526	Surgical outcome of children with medulloblastoma: a retrospective study of a 405-patient series from Children's Cancer Hospital Egypt (CCHE-57357). Child's Nervous System, 2021, 37, 1931-1940.	1.1	1
527	Observed-to-expected incidence ratios of second malignant neoplasms after radiation therapy for medulloblastoma: A Surveillance, Epidemiology, and End Results analysis. Cancer, 2021, 127, 2368-2375.	4.1	3
528	Inter and intra-tumoral heterogeneity as a platform for personalized therapies in medulloblastoma. , 2021, 228, 107828.		7
529	Clinical Audit of Survival Outcomes and Prognostic Factors in Adolescents and Adults with Medulloblastoma. Journal of Adolescent and Young Adult Oncology, 2022, 11, 68-77.	1.3	5
530	Radiation therapy for infants with cancer. Pediatric Blood and Cancer, 2021, 68, e28700.	1.5	3
531	An efficient and novel treatment regimen including temozolomide for medulloblastoma: a case study. Journal of Radiotherapy in Practice, 0, , 1-6.	0.5	0
532	What does a non-response to induction chemotherapy imply in high-risk medulloblastomas?. Journal of Neuro-Oncology, 2021, 153, 425-440.	2.9	0
533	Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination. Cell Reports, 2021, 35, 109302.	6.4	19
534	Overview and recent advances in the targeting of medulloblastoma cancer stem cells. Expert Review of Anticancer Therapy, 2021, 21, 957-974.	2.4	5
535	Development of Randomized Trials in Adults with Medulloblastomaâ€”The Example of EORTC 1634-BTG/NOA-23. Cancers, 2021, 13, 3451.	3.7	8
536	Tumor cells generate astrocyte-like cells that contribute to SHH-driven medulloblastoma relapse. Journal of Experimental Medicine, 2021, 218, .	8.5	19
537	Magnetic resonance radiomics features and prognosticators in different molecular subtypes of pediatric Medulloblastoma. PLoS ONE, 2021, 16, e0255500.	2.5	16
538	Treatment barriers and clinical outcome of children with medulloblastoma in China: a report from the Chinese Children's Cancer Group (CCCC). Neuro-Oncology Advances, 2021, 3, vdab134.	0.7	1
539	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. JAMA Oncology, 2021, 7, 1313.	7.1	61
540	Embryonal Tumors. Pediatric Oncology, 2010, , 89-114.	0.5	1
541	Embryonal Tumors. Pediatric Oncology, 2004, , 83-105.	0.5	4
542	Cancer of the Central Nervous System. , 2008, , 1075-1136.		1
543	Cancer and the Nervous System. , 2008, , 1357-1383.		1

#	ARTICLE	IF	CITATIONS
544	Chemotherapy of Medulloblastoma. , 2006, , 407-425.		1
545	Primary Tumors of the Central and Peripheral Nervous System. , 2003, , 827-863.		7
546	Pediatric Central Nervous System Tumors. , 2010, , 1111-1129.		1
547	Tumors of the Brain and Spine. , 2012, , 1339-1387.		1
548	Cancer of the Central Nervous System. , 2014, , 938-1001.e16.		1
549	Biology and therapy of malignant solid tumors in childhood. Cancer Chemotherapy and Biological Response Modifiers, 2003, 21, 683-707.	0.5	10
550	A Mouse Model for Medulloblastoma and Basal Cell Nevus Syndrome. , 2001, 53, 307.		1
552	Medulloblastoma. Current Opinion in Neurology, 1999, 12, 681-685.	3.6	20
553	Medulloblastoma in China: Clinicopathologic Analyses of SHH, WNT, and Non-SHH/WNT Molecular Subgroups Reveal Different Therapeutic Responses to Adjuvant Chemotherapy. PLoS ONE, 2014, 9, e99490.	2.5	24
554	High OCT4A levels drive tumorigenicity and metastatic potential of medulloblastoma cells. Oncotarget, 2017, 8, 19192-19204.	1.8	19
555	Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model. Oncotarget, 2017, 8, 56747-56757.	1.8	22
556	Childhood Medulloblastoma: Current Therapies, Emerging Molecular Landscape and Newer Therapeutic Insights. Current Neuropharmacology, 2018, 16, 1045-1058.	2.9	39
557	Survival and prognostic factors in childhood medulloblastoma: A Brazilian single center experience from 1995 to 2016. , 2019, 10, 120.		9
558	Leptomeningeal dissemination: a sinister pattern of medulloblastoma growth. Journal of Neurosurgery: Pediatrics, 2019, 23, 613-621.	1.3	29
559	Radiation Therapy against Pediatric Malignant Central Nervous System Tumors : Embryonal Tumors and Proton Beam Therapy. Journal of Korean Neurosurgical Society, 2018, 61, 386-392.	1.2	3
560	Reducing late effects of radiotherapy in average risk medulloblastoma. Chinese Clinical Oncology, 2014, 3, 4.	1.2	19
561	Medulloblastomas: New directions in risk stratification. Neurology India, 2006, 54, 16.	0.4	22
562	Lomustine induced acute pulmonary toxicity in a pediatric medulloblastoma survivor. South Asian Journal of Cancer, 2017, 06, 038-039.	0.6	1

#	ARTICLE	IF	CITATIONS
563	Survival and prognostic factors in pediatric patients with medulloblastoma in southern Thailand. Journal of Pediatric Neurosciences, 2018, 13, 150.	0.3	16
564	<i>MYCC</i> and <i>MYCN</i> Oncogene Amplification in Medulloblastoma. Archives of Pathology and Laboratory Medicine, 2002, 126, 540-544.	2.5	152
565	Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases. Clinics, 2017, 72, 294-304.	1.5	5
566	Postoperative hydrocephalus management may cause delays in adjuvant treatment following paediatric posterior fossa tumour resection: a multicentre retrospective observational study. Child's Nervous System, 2022, 38, 311-317.	1.1	6
567	Experience of 20 years in Management of Medulloblastoma ( A long term Retro spective study). The Egyptian Journal of Hospital Medicine, 2000, 1, 138-147.	0.1	0
569	Supratentorial Primitive Neuroectodermal Tumors. , 2005, , 675-681.		0
571	Pediatric Neuro-oncology. , 2006, , 299-312.		0
572	Tumors of the Central Nervous System. , 2009, , 1-8.		0
573	Treatment of Medulloblastoma in adults. , 2009, , 41-44.		0
574	Tumors of the Brain and Spinal Cord. , 2009, , 601-720.		2
579	Twelve Clinically Significant Points in Medulloblastoma(<SPECIAL ISSUE>Pediatric Neurosurgery and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.0	0
580	Pediatric Brain Tumors: Application of Stratification Criteria to Refine Patient Management. Pediatric Cancer, 2012, , 211-222.	0.0	1
581	Cancer and the Nervous System. , 2012, , 1158-1181.		0
583	Event-Free Survival of Children with Average-Risk Medulloblastoma: Treatment with Craniospinal Radiation Followed by Adjuvant Chemotherapy. Pediatric Cancer, 2013, , 93-101.	0.0	0
584	Tumeurs de la fosse postÃ©rieure. , 2013, , 141-149.		0
585	Supratentorial Primitive Neuroectodermal Tumor: Therapy. Pediatric Cancer, 2013, , 253-264.	0.0	0
587	Medulloblastomas: Survival Differences Between Children and Adults. Tumors of the Central Nervous System, 2014, , 121-127.	0.1	0
588	Paediatric Neuro-Oncology. , 2014, , 365-376.		0

#	ARTICLE	IF	CITATIONS
589	Tumors of the Central Nervous System. , 2014, , 555-568.		0
590	Hirntumoren. , 2014, , 571-586.		0
591	Detection of RAF fusion transcripts in FFPE samples of Medullablastoma and Ependymom in Iraqi children with RT-RQPCR assays. Baghdad Science Journal, 2014, 11, 1411-1419.	0.6	0
593	Pineal Region Tumors: Viewpointâ€”Surgery. , 2015, , 459-468.		1
594	Medulloblastom im Kindes- und Jugendalter. , 2015, , L6b.1-L6b.4.		0
595	Pediatric Disorders: Viewpointâ€”Surgery. , 2015, , 415-426.		0
596	Treatment of Medulloblastoma: Chemotherapy. , 2015, , 349-361.		0
597	An Investigation of the Prognostic Factors in Progressive or Recurrent Paediatric Solid Tumour. Journal of Pediatric Oncology, 2015, 3, 16-23.	0.1	0
598	Therapeutic Strategies for Medulloblastoma based on its Molecular and Genetic Diagnosis. Japanese Journal of Neurosurgery, 2016, 25, 307-314.	0.0	0
599	Treatment of medulloblastoma in children and adolescents. Revista Da AssociaÃ§Ã£o MÃ©dica Brasileira, 2016, 62, 298-302.	0.7	2
600	Factors affecting the prognosis of children with medulloblastoma: A single institution retrospective analysis of 40 cases. Translational Neuroscience and Clinics, 2017, 3, 16-27.	0.1	0
601	Treatment Outcome and Prognostic Factors for Pediatric Medulloblastoma Patients: The Egyptian National Cancer Institute Experience. Journal of Cancer Therapy, 2017, 08, 699-713.	0.4	0
602	Craniospinal Irradiation. , 2018, , 453-467.		0
603	Risk factors for the prognosis of pediatric medulloblastoma: a retrospective analysis of 40 cases. Clinics, 2017, 72, 790-790.	1.5	2
604	ZNS-Tumoren. , 2018, , 359-418.		2
605	Medulloblastoma: de la clasificaciÃ³n histolÃ³gica a la molecular. Medicina UPB, 2018, 37, 47-54.	0.1	0
606	Adult Medulloblastoma. , 2018, , 377-397.		1
607	Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Children with Brain Tumors : Review of Single Center Experience. Journal of Korean Neurosurgical Society, 2018, 61, 393-401.	1.2	4



#	ARTICLE	IF	CITATIONS
608	Çocukluk Çağında medulloblastom olgularında P53, ERBB2, c-Kit ve BCL2 Ekspresyonunun prognostik ve klinik önemi. Cukurova Medical Journal, 2019, 44, 1-7.	0.2	0
610	Effects of the growth pattern of medulloblastoma on short-term neurological impairments after surgery: results from the prospective multicenter HIT-SIOP PNET 4 study. Journal of Neurosurgery: Pediatrics, 2020, 25, 425-433.	1.3	2
611	A Retrospective Analysis of the Demographics, Treatment, and Survival Outcomes of Patients with Desmoplastic Nodular Medulloblastoma Using the Surveillance, Epidemiology, and End Results (SEER) Database. Cureus, 2020, 12, e9042.	0.5	2
613	Medulloblastoma, Primitive Neuroectodermal Tumors, and Pineal Tumors. , 2008, , 343-430.		1
614	CNS Tumors in Children. Medical Radiology, 2008, , 547-556.	0.1	0
615	Differentiation of Outcomes by Treatment Regimen and Histology in Central Nervous System Primary Embryonal Tumors. World Neurosurgery, 2020, 141, e289-e306.	1.3	2
616	Two machine learning methods identify a metastasis-related prognostic model that predicts overall survival in medulloblastoma patients. Aging, 2020, 12, 21481-21503.	3.1	3
617	Adult medulloblastoma associated with syringomyelia: a case report. Cancer Biology and Medicine, 2012, 9, 137-40.	3.0	5
618	Adult Desmoplastic Medulloblastoma. Saudi Journal of Medicine and Medical Sciences, 2017, 5, 181-184.	0.8	0
619	Comprehensive identification of a two-genesignature as a novel potential prognostic model for patients with medulloblastoma. American Journal of Translational Research (discontinued), 2020, 12, 1600-1613.	0.0	1
620	Postoperative evaluation for disseminated medulloblastoma involving the spine: contrast-enhanced MR findings, CSF cytologic analysis, timing of disease occurrence, and patient outcomes. American Journal of Neuroradiology, 2000, 21, 1757-65.	2.4	54
621	SIOP PNET5 MB Trial: History and Concept of a Molecularly Stratified Clinical Trial of Risk-Adapted Therapies for Standard-Risk Medulloblastoma. Cancers, 2021, 13, 6077.	3.7	16
622	Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies. Methods in Molecular Biology, 2022, 2423, 215-235.	0.9	3
623	Molecular and clinical correlates of medulloblastoma subgroups: A narrative review. Glioma (Mumbai, India), 2021, 4, 92.	0.1	2
624	Magnetic Resonance Imaging in the Contemporary Management of Medulloblastoma: Current and Emerging Applications. Methods in Molecular Biology, 2022, 2423, 187-214.	0.9	3
625	Clinical Trials in High-Risk Medulloblastoma: Evolution of the SIOP-Europe HR-MB Trial. Cancers, 2022, 14, 374.	3.7	16
626	Childhood Medulloblastoma: An Overview. Methods in Molecular Biology, 2022, 2423, 1-12.	0.9	5
627	Prognostic impact of semantic MRI features on survival outcomes in molecularly subtyped medulloblastoma. Strahlentherapie Und Onkologie, 2022, 198, 291.	2.0	1

#	ARTICLE	IF	CITATIONS
628	Second-look surgery after pediatric brain tumor resection – Single center analysis of morbidity and volumetric efficacy. Brain and Spine, 2022, 2, 100865.	0.1	1
629	Refining M1 stage in medulloblastoma: criteria for cerebrospinal fluid cytology and implications for improved risk stratification from the HIT-2000 trial. European Journal of Cancer, 2022, 164, 30-38.	2.8	3
630	Clinical and molecular characterization of isolated M1 disease in pediatric medulloblastoma: experience from the German HIT-MED studies. Journal of Neuro-Oncology, 2022, 157, 37-48.	2.9	2
631	Elevated Kir2.1/nuclear N2ICD defines a highly malignant subtype of non-WNT/SHH medulloblastomas. Signal Transduction and Targeted Therapy, 2022, 7, 72.	17.1	4
632	Machine-learning approach to predict molecular subgroups of medulloblastoma using multiparametric MRI-based tumor radiomics. British Journal of Radiology, 2022, 95, 20211359.	2.2	6
633	Neuro-cognitive function and survival in children with average-risk medulloblastoma treated with hyperfractionated radiation therapy alone: long-term mature outcomes of a prospective study. Neuro-Oncology Practice, 0, , .	1.6	0
634	Risk Factors for Survival in Patients With Medulloblastoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2022, 12, 827054.	2.8	7
635	Pediatric versus Adult Medulloblastoma: Towards a Definition That Goes beyond Age. Cancers, 2021, 13, 6313.	3.7	4
637	Adult desmoplastic medulloblastoma. Saudi Journal of Medicine and Medical Sciences, 2017, 5, 181.	0.8	0
638	Enrichment of Tumor-Infiltrating B Cells in Group 4 Medulloblastoma in Children. International Journal of Molecular Sciences, 2022, 23, 5287.	4.1	4
639	Intraoperative MRI versus intraoperative ultrasound in pediatric brain tumor surgery: is expensive better than cheap? A review of the literature. Child's Nervous System, 2022, 38, 1445-1454.	1.1	12
640	New Developments in the Pathogenesis, Therapeutic Targeting, and Treatment of Pediatric Medulloblastoma. Cancers, 2022, 14, 2285.	3.7	15
641	Factors influencing outcomes of older children with medulloblastoma over 15Âyears in Peru, a resourceâ€limited setting. Pediatric Blood and Cancer, 2022, 69, e29770.	1.5	3
643	Omission of Upfront Craniospinal Irradiation in Patients with Low-Risk WNT-Pathway Medulloblastoma Is Associated with Unacceptably High Risk of Neuraxial Failure. Clinical Cancer Research, 2022, 28, 4180-4185.	7.0	12
644	Postchemotherapy gross residual tumor in nonâ€highâ€risk neuroblastoma: Clinical significance and the role of adjuvant therapy. Pediatric Blood and Cancer, 0, , .	1.5	0
645	The Current State of Radiotherapy for Pediatric Brain Tumors: An Overview of Post-Radiotherapy Neurocognitive Decline and Outcomes. Journal of Personalized Medicine, 2022, 12, 1050.	2.5	7
646	A Phase I Trial of TB-403 in Relapsed Medulloblastoma, Neuroblastoma, Ewing Sarcoma, and Alveolar Rhabdomyosarcoma. Clinical Cancer Research, 2022, 28, 3950-3957.	7.0	5
647	WNT medulloblastoma limbo: How low can we go?. Clinical Cancer Research, 0, , .	7.0	1

#	ARTICLE	IF	CITATIONS
648	Meta of classical chemotherapy compared with high-dose chemotherapy and autologous stem cell rescue in newly diagnosed medulloblastoma after radiotherapy. <i>Medicine (United States)</i> , 2022, 101, e29372.	1.0	0
649	Effects of Proton Craniospinal Radiation on Vertebral Body Growth Retardation in Children. <i>International Journal of Radiation Oncology Biology Physics</i> , 2023, 115, 572-580.	0.8	2
650	Imaging Embryonal Tumors of the Central Nervous System. <i>Advances in Clinical Radiology</i> , 2022, 4, 215-229.	0.2	0
651	Molecular testing for adolescent and young adult central nervous system tumors: A Canadian guideline. <i>Frontiers in Oncology</i> , 0, 12, .	2.8	6
652	Early outcome after craniospinal irradiation with pencil beam scanning proton therapy for children, adolescents and young adults with brain tumors. <i>Pediatric Blood and Cancer</i> , 0, , .	1.5	1
654	Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF- $\kappa$ B-TGM2 driven tumor inflammation. , 2023, 11, e005871.		7
655	Precision based approach to tailoring radiotherapy in the multidisciplinary management of pediatric central nervous system tumors. <i>Journal of the National Cancer Center</i> , 2023, 3, 141-149.	7.4	0
656	WNT-pathway medulloblastoma: what constitutes low-risk and how low can one go?. <i>Oncotarget</i> , 2023, 14, 105-110.	1.8	4
657	Prognostic value of microRNA-125a expression status in molecular groups of pediatric medulloblastoma. <i>Child's Nervous System</i> , 0, , .	1.1	1
658	Resection cavity auto-contouring for patients with pediatric medulloblastoma using only CT information. <i>Journal of Applied Clinical Medical Physics</i> , 0, , .	1.9	2
660	Treatment of hydrocephalus following posterior fossa tumor resection: a multicenter collaboration from the Hydrocephalus Clinical Research Network. <i>Journal of Neuro-Oncology</i> , 2023, 163, 123-132.	2.9	1
661	Neurocognitive and radiological follow-up of children under 5 years of age treated for medulloblastoma according to the HIT-SKK protocol. <i>Journal of Neuro-Oncology</i> , 2023, 163, 195-205.	2.9	0
662	Clinical, Histological, and Molecular Prognostic Factors in Childhood Medulloblastoma: Where Do We Stand?. <i>Diagnostics</i> , 2023, 13, 1915.	2.6	1
663	Questions and answers in the management of children with medulloblastoma over the time. How did we get here? A systematic review. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	0
664	Medulloblastomas in Pediatric and Adults. <i>Advances in Experimental Medicine and Biology</i> , 2023, , 117-152.	1.6	0
665	Efficacy of intrathecal methotrexate in children with high-risk medulloblastoma over three years: a retrospective study from a single center. <i>Journal of Neuro-Oncology</i> , 0, , .	2.9	1
667	Posterior fossa tumors in children: current insights. <i>European Journal of Pediatrics</i> , 2023, 182, 4833-4850.	2.7	1
668	Prognostic significance of molecular subgroups in survival outcome for children with medulloblastoma in Malaysia. <i>Frontiers in Oncology</i> , 0, 13, .	2.8	1

#	ARTICLE	IF	CITATIONS
669	Recent Advances in Pediatric Medulloblastoma. Current Neurology and Neuroscience Reports, 0, , .	4.2	1
670	Evolution of Systemic Therapy in Medulloblastoma Including Irradiation-Sparing Approaches. Diagnostics, 2023, 13, 3680.	2.6	1
671	Evolution of neurosurgical advances and nuances in medulloblastoma therapy. Child's Nervous System, 0, , .	1.1	0
672	Clinico-Radiological Outcomes in WNT-Subgroup Medulloblastoma. Diagnostics, 2024, 14, 358.	2.6	0
673	Heterogeneity and tumoral origin of medulloblastoma in the single-cell era. Oncogene, 2024, 43, 839-850.	5.9	0
674	The clinical significance of sub-total surgical resection in childhood medulloblastoma: a multi-cohort analysis of 1100 patients. EClinicalMedicine, 2024, 69, 102469.	7.1	0